Etanordes 35 mg TABLETS
PDF Leaflet Revision Date: 26 February 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of osteoporosis in postmenopausal women.
Dosage (summary)
One 35 mg tablet orally, once a week.
Special Populations
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- Polyvalent cations (calcium, magnesium, iron, aluminium)
Contraindications
- Hypersensitivity to risedronate
- Hypocalcaemia
- Advanced renal impairment (creatinine clearance < 30 ml/min)
Common side effects
- Dyspepsia
- Nausea
- Abdominal pain
- Musculoskeletal pain
- Osteonecrosis of the jaw
Counselling Points
- Take with a full glass of water
- Remain upright for 30 mins after taking
- Avoid food/drinks containing polyvalent cations around dosing time
Serious warnings
- Upper gastrointestinal disorders
- Atypical femur fractures
- Osteonecrosis of the jaw
Important Disclaimer
The Etanordes 35 mg TABLETS professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
